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Strategies for the Synthesis of Spiropiperidines – A Review of the 
Last 10 Years   
Samuel D. Griggs,
a
 Daniel T. Tape
 b
 and Paul A. Clarke
 
*
a 
Spiropiperidines have gained in popularity in drug discovery programmes as medicinal chemists explore new areas of 
three-dimensional chemical space. This review focuses on the methodology used for the construction of 2-, 3- and 4-
spiropiperidines, covering the literature from the last 10 years. It classifies the synthesis of each of the types of 
spiropiperidine by synthetic strategy: the formation of the spiro-ring on a preformed piperidine ring, and the formation of 
the piperidine ring on a preformed carbo- or heterocyclic ring. While 3- and 4-spiropiperidines are predominantly 
synthesised for drug discovery projects, 2-spiropiperidines are synthesised en route to natural products. The lack of 2-
spiropiperidines in drug discovery is presumably due to limited general procedures for their synthesis.   
1. Introduction 
The identification and generation of high quality lead 
compounds are imperative in the initial stages of drug 
discovery. With a greater understanding of chemical and 
biological space, there has been a much greater emphasis on 
the exploration and exploitation of a molecule’s three-
dimensional nature.1 Spirocycles are frequently used as 
scaffolds and pharmacophores in drug discovery as a 
consequence of their structural complexity and rigidity, and 
their ability to be elaborated along well-defined vectors.2 
Owing to the frequency of nitrogen containing heterocycles in 
drug discovery and the growing desire to explore three-
dimensional space, aza-spirocycles are fast becoming highly 
desirable targets for synthesis. For example, the 2-
spiropiperidine-containing natural product histrionicotoxin 
was identified as an acetylcholine receptor inhibitor,3 a 3-
spiropiperidine was reported by Novartis as a ghrelin receptor 
agonist in patent US 20120302540,4 and GlaxoSmithKline have 
reported a 4-spiropiperidine as a fatty acid synthase inhibitor 
in patent WO 2013177253.5 n 2009 Troin reviewed the 
synthesis of spirocyclic piperidines as important building blocks 
in medicinal chemistry.6 The review highlighted the diverse 
approaches made towards the synthesis of 3- and 4-
spiropiperidines. In this review, we present a summary of the 
past 10 years literature on the synthesis of spiropiperidines, 
including the relatively under-explored synthesis of 2-
spiropiperidines, which were not covered in Troin’s review. In 
each case, we will discuss two approaches towards the 
synthesis of the spirocycle; firstly, the formation of the 
spirocycle on a preformed piperidine ring, and secondly, the 
formation of the spirocycle on a preformed 
carbocyclic/heterocyclic ring.  
2. 2-Spiropiperidines 
2.1 2-Spiropiperidine formation on a preformed piperidine ring. 
The synthesis of 2-spiropiperidines from a preformed 
piperidine ring is an under explored method for their 
synthesis. The two presented methods proceed via a reductive 
lithiation and a 1,3-dipolar cycloaddition. It is clear from the 
lack of literature precedent that new methods for the 
synthesis of 2-spiropiperidines from a preformed piperidine 
ring is a relatively novel approach.  
A new route to tertiary α-amino stereocentres was 
developed by Rychnovsky in 2008, which in turn allows the 
synthesis of 2-spiropiperidines.7 α-Amino nitrile 1 was 
alkylated to give substituted piperidine 2, which then 
underwent a reductive cyclisation onto the alkene to yield 2-
spiropiperidine 3 in good yield and high diastereoselectivity 
(Scheme 1). The reaction has been demonstrated to give 2-
spiropiperidines with five and six membered carbocyclic rings 
with a range of tethers, in moderate to good yield. 
Ryan and co-workers synthesised (‒)-
perhydrohistrionicotoxin 6 on gram-scale in batch, as well as 
through flow. The natural product contains a 2-spiropiperidine 
core, which was accessed through isoxazolidine 4 (Scheme 2).8 
Under microwave irradiation at 184 °C, isoxazolidine 4 
underwent a retro [3+2] cycloaddition followed by 1,3-dipolar 
cycloaddition to give 2-spiropiperidine 5 in good yield. The N-O 
bond was then reductively cleaved to give the natural product 
2-spiropiperidine 6 in high yield. 
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2.2 2-Spiropiperidine formation on a preformed 
carbocyclic/heterocyclic ring. 
The formation of a 2-spiropiperidine from a preformed 
carbocyclic or heterocyclic ring is the most common strategy 
for the synthesis of 2-spiropiperidines. Methods include [6+3], 
[3+2], and 1,3-dipolar cycloadditions, ring closing metathesis, 
and the use of commercially available SnAP reagents.  
A 1,3-dipolar cycloaddition approach was reported by 
Coldham in 2017 for the synthesis of spirocyclic amines.9 
Condensation of hydroxylamine with an open chain ketone 7 
followed by displacement of the chlorine gave the 1,3-dipole 8, 
which underwent cycloaddition in PhMe under reflux to give 
tricycle 9 (Scheme 3). The N-O bond was then reductively 
cleaved with Zn/AcOH to yield 2- spiropiperidine 10 in 
excellent yield. 
 
 
 
 
 
 
 
Scheme 1 Rychnovsky’s synthesis of 2-spiropiperidines through alkylation and 
reductive cyclisation.  
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Scheme 2 Retro [3+2] followed by a 1,3-dipolar cycloaddition to afford the 2-
spiropiperidine core of (‒)-perhydrohistrionicotoxin. 
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Scheme 3 1,3-Dipolar cycloaddition to yield a tricyclic precursor to 2-
spiropiperidines 
 
Tricyclic, bridged 2-spiropiperidines have been synthesized by 
means of a silver-catalysed diastereoselective [6+3] 
cycloaddition in a reaction developed by Guo and coworkers.
10
 
Tropone 11 is treated with an azomethine ylide, generated 
from precursor 12 which is derived from homoserine lactone 
(Scheme 4). A range of silver catalysts were screened with 
different bases, with AgOAc (10 mol%) and DBU (20 mol%) 
yielding the best results. The 1,3-dipolar cycloaddition 
proceeded under mild conditions, giving a range of tricyclic 2-
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spiropiperidines 13 in moderate to excellent yields, with 
diastereoselectivities >20:1. 
 
Scheme 4 [6+3] Cycloaddition of tropone to homoserine lactone derived 
azomethine ylides. 
 
 
 
Scheme 5 Aza-Achmatowicz rearrangement to afford the 2-spiropiperidine core 
of pinnaic acid.  
Marquez efficiently accessed the 2-spiropiperidine core of 
the natural product pinnaic acid via an aza-Achmatowicz 
rearrangement (Scheme 5).
11
 Upon oxidation of the furan and 
subsequent rearrangement of amine 14, the hemi-aminal was 
allylated under Lewis acidic conditions to give 2-spiropiperidin-
3-one 15 in good yield. Selective 1,4-reduction was achieved 
using Stryker’s reagent and deoxygenation occurred with 
tosylhydrazine and DIBAL-H to give 2-spiropiperidine 16 in 
moderate yield.  
SnAP (tin amine protocol) reagents are a series of 
commercially available reagents developed by Bode.
12
 
Treatment of SnAP reagents 17 and 21 with ketones gave rise 
to imines 19 and 23, which underwent homolytic cleavage of 
the C-Sn bond and a radical addition to the imine upon 
addition of Cu(OTf)2, giving spirocyclic heterocycles 20 and 24 
respectively (Scheme 6).
13
 This robust procedure allows 
efficient access to a range of substituted spiropiperidines and 
does not require protection of the piperidine nitrogen, 
however, it does involve the use of potentially toxic organotin 
reagents.  
 
 
Scheme 6 Synthesis of 2-spirospiperidines using SnAP reagents. 
 
 
Scheme 7 Trianion synthon approach to the synthesis of 2-spiropiperidines. 
 
 
Scheme 8 Ring closing metathesis to form the 2-spiropiperidine – a type II β-turn 
peptide isostere.  
Rychnovsky’s approach to the synthesis of spirocyclic 
heterocycles was reversed in later studies, forming the 
carbocyclic ring prior to the heterocyclic ring.
14
 Just one 
example of a 2-spiropiperidine is reported utilising this 
approach. The α-amino nitrile 25 was utilised as a trianion 
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synthon – first to perform a double alkylation with dibromo 
ketal 26 to form the carbocyclic ring of 27, followed by a 
reductive cyclisation to give 2-spiropiperidine 28 (Scheme 7).  
A ring closing metathesis was reported by Silvani for the 
synthesis of a spiropiperidine-3,3’-oxindole scaffold as a type II 
β-turn peptide isostere in 2010.
15
 Oxindole 29, synthesised 
from isatine via Grignard addition into an imine,
16 
underwent 
N-acylation followed by N-allylation to give diene 30 (Scheme 
8). 2-Spiropiperidine 31 was formed in high yield through a 
ring closing metathesis of 30 with Grubbs II catalyst, followed 
by hydrogenation of the double bond.  
Robinson and co-workers developed a route to 
enantiopure 2-azaspirocycles in 2013.
17
 A cross-metathesis 
between N-protected allylglycine and methylenecyclohexane 
gave enantiopure cyclisation precursor 32, which then 
underwent acid mediated cyclisation with TfOH to give 2-
spiropyrrolidine 33 in good yield (Scheme 9). To access the 2-
spiropiperidine, the ester was first reduced to alcohol 34 with 
LiAlH4, followed by treatment under Appel conditions to access 
the bromide. Ring expansion occurred through formation of an 
aziridinium intermediate and trapping with the bromide. The 
bromide was found to be silica unstable, so it was converted to 
the thiocyanate analogue 35 in good yield, though with a slight 
erosion of %ee. 
A two-step synthesis of 2-spiropiperidines (Scheme 10) was 
recently presented by Clarke.
18
 δ-Amino-β-ketoesters 38 were 
formed through Mannich addition of the dianion of methyl 
acetoacetate 37 onto N-Boc imines, which were formed in situ 
from N-Boc sulfone precursor 36. The N-Boc-δ-amino-β-
ketoesters were deprotected with HCl in dioxane and the HCl 
salts of δ-amino-β-ketoesters 38 were then ‘cracked’ in the 
presence of a cyclic ketone to give highly functionalised 2-
spiropiperidines 39. The synthesis has been shown to proceed 
with aliphatic, aromatic and heteroaromatic C-6 substituents, 
with examples of carbocyclic and heterocyclic spirocycles at C-
2. 2-Spiropiperidines are formed in good to excellent yields 
with moderate diastereoselectivities. The 2-spiropiperidines 
were further functionalised to generate a small library of 
medicinally relevant molecules. 
 
Scheme 9 Ring expansion of 2-spiropyrrolidines to afford 2-spiropiperidines with 
high enantiomeric excess. 
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Scheme 10 Two-step synthesis of 2-spiropiperidines from a δ-amino-β-ketoester. 
Padwa reported an alternative route to access the 2-
spiropiperidine core of (±)-2,7,8-epi-perhydrohistrionicotoxin, 
and in turn a new approach for the synthesis of 2-
spiropiperidines.19 Oxime 40 underwent addition to diene 41 
followed by a [3+2] annulation to afford cycloadducts 42 and 
43 in high yield and a 1:1 ratio (Scheme 11). The ratio of 
products was insignificant as the only stereochemical 
difference was the oxo bridge, which was subsequently 
destroyed through reductive cleavage with Na/Hg amalgam to 
give spiropiperidine 44. The sulfone was then reduced using 
AIBN/Bu3SnH to yield 2-spiropiperidine 45 in excellent yield.  
 
 
Scheme 11 [3+2] annulation followed by reductive cleavage en route to (±)-2,7,8-
epi-perhydrohistrionicotoxin.  
Nankakurines are lycopodium alkaloids that contain a 2-
spiropiperidine motif that are isolated from mosses. Over the 
last ten years there have been multiple syntheses of the 
nankakurines, some of which are presented below.  
Overman and co-workers presented an intramolecular 
azomethine imine cycloaddition with hydrazide 46 to give 
tetracyclic pyrazolidine 47 in high yield (Scheme 12).
20
 The N-N 
bond was subsequently cleaved with SmI2, and selective 
reductive amination gave cyclisation precursor 48. 
Hydrogenation followed by reduction gave diamine alcohol 49, 
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and selective O-mesylation allowed cyclisation to proceed, 
giving 2-spiropiperidine 50 in excellent yield. Overman also 
demonstrated the use of a sulfonamide-terminated aza-Prins 
cyclisation with carbamate 51 and 1 equivalent of 
formaldehyde (Scheme 13).
21
 Whilst the reaction proceeded in 
low yield, it enabled fast access to 2-spiropiperidine 52, just 
two steps from the natural product.   
 
 
Scheme 12 Nankakurine via a SmI2 mediated N-N bond cleavage and SN2 
cyclisation. 
 
 
Scheme 13 Sulfonamide-terminated aza-Prins cyclisation onto an iminium.  
 
 
Scheme 14 Waters’ ring closing metathesis to form the nankakurine core. 
Waters’ approach to the nankakurine core was via a ring 
closing metathesis.
22
 Sequential addition of allylamine and allyl 
magnesium bromide into ketone 53 furnished diene 54 in high 
yield (Scheme 14). The spiropiperidine was formed through 
ring closing metathesis of diene 54 and subsequent 
hydrogenation to give core 55 in excellent yield. 
 
3. 3-Spiropiperidines 
3.1 3-Spiropiperidine formation on a preformed piperidine ring.  
The synthesis of 3-spiropiperidines is represented by an equal 
number of the two synthetic strategies. Methodology used to 
form the carbocyclic or heterocyclic ring on to the piperidine ring 
includes radical cyclisations with SmI2, organolanthanide addition to 
ketones, and palladium-mediated intramolecular cyclisations. 
Procter developed a samarium(II)-mediated stereoselective 
cyclisation for the synthesis of aza-spirocycles.
23
 Unsaturated 
ketolactam 56 underwent a sequential conjugate-reduction-
aldol cyclisation when treated with SmI2 to give a spirocyclic 
lactam, which was reduced with BH3 to give 3-spiropiperidine 
57 in excellent yield (Scheme 15). The cyclisation has been 
demonstrated to give a range of substituted spirocyclic 
cyclopentane rings. 
An intramolecular Mitsunobu reaction was the strategy 
employed by Micheli and co-workers to give 3-
spiropiperidines.
24
 Michael addition of ester 58 on to ethyl 
acrylate and complete reduction of the glutarimide ring and 
esters gave diol 59 (Scheme 16). Treatment of diol 59 under 
Mitsunobu conditions initiated cyclisation to form the pyran 
ring and consequently a 3-spiropiperidine 60. The chemistry 
has also been demonstrated with the synthesis of 
tetrahydrofuran and oxetane spirocycles.  
Enolate chemistry of ester functionalised piperidine 61 was 
utilised to access the 3-spiropiperidine precursor 62 in a report 
by Su in 2011.
25
 Monotosylation of diol 62 followed by 
intramolecular cyclisation gave 3-spiropiperidine 63 in 
moderate yield (Scheme 17). A synthesis of a 4-spiropiperidine 
bearing an oxetane is also presented using the same method.
25
   
Pfefferkorn developed an intramolecular palladium-
catalysed α-arylation reaction for the synthesis of a 3-
spiropiperidine.
26
 Oxidative addition occurs with bromide 64 
and palladium, and subsequent reaction with the amide 
enolate furnished 3-spiropiperidine 65 in moderate yield 
(Scheme 18), for use as a scaffold in drug discovery. 
 
 
 
 
Scheme 15 Samarium(II)-mediated stereoselective cyclisation for the formation 
of 3-spiropiperidines.  
 
Page 5 of 14 Organic & Biomolec lar Chemi try
2U
JD
QLF
	%
LRP
ROH
FX
ODU
&K
HP
LVW
U\
$F
FH
SWH
G0
DQ
XV
FUL
SW
Pu
bl
ish
ed
 o
n 
04
 Ju
ly
 2
01
8.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f Y
or
k 
on
 7
/5
/2
01
8 
8:
58
:2
6 
A
M
. 
View Article Online
DOI: 10.1039/C8OB01271G
ARTICLE Journal Name 
6 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
 
Scheme 16 Intramolecular Mitsunobu to access 3-spiropiperidines. 
 
 
 
Scheme 17 Monotosylation and deprotonation to initiate cyclisation to form a 3-
spiropiperidine bearing an oxetane ring. 
  
 
 
Scheme 18 Intramolecular arylation of a functionalised amide enolate. 
Nicolau and co-workers introduced a new route to 3-
spiropiperidines from N-Boc anilines 66 (Scheme 19).
27
 A 
directed lithiation of aniline 66 with t-BuLi, metal exchange 
with LaCl3 and addition to N-protected piperidone 67 gave rise 
to 3-spiropiperidine 68 in good yield. The 3-spiropiperidines 
presented are derived from a range of p-substituted anilines 
and are compatible with Boc-, Cbz-, Ts- and methyl carbamate 
protected 3-piperidones. 
 
 
 
Scheme 19 Lithium-Lanthanum exchange and subsequent addition to N-
protected piperidone to yield 3-spiropiperidines.  
 
3.2 3-Spiropiperidine formation on a preformed 
carbocyclic/heterocyclic ring. 
Approaches to 3-spiropiperidines by the formation of the 
piperidine ring on a preformed carbocyclic or heterocyclic ring 
employ a diverse range of chemistry. Palladium-mediated 
cyclisations, asymmetric Michael additions, cycloadditions, and 
multicomponent reactions are representative strategies that 
give rise to 3-spiropiperidines. 
A one-pot multicomponent synthesis of 
trifluoromethylated 3-spiropiperidines was reported by Song 
and co-workers in 2016 (Scheme 20).
28
 The four-component 
reaction proceeded at room temperature under catalyst-free 
conditions to give 3-spiropiperidines 72 in high yields. Michael-
addition of β-ketoester 70 to isoxazolone 69, followed by 
addition into the imine derived from condensation of NH4OAc 
with aldehyde 71, gave an open chain amine. Subsequent 
intramolecular cyclisation by aminal formation gave the 3-
spiropiperidine 72. The synthesis has been demonstrated with 
a range of aromatic aldehydes and isoxazol-5-ones.  
 
 
 
Scheme 20 One-pot, four component synthesis of trifluoromethylated 3-
spiropiperidines.  
A TfOH catalyst was used for a tandem semi-pinacol 
rearrangement/alkyne-aldehyde metathesis, in the synthesis 
of 3-spiropiperidines bearing a cyclopentanone spirocycle in a 
report by Yeh in 2011.
29
 Epoxide 73 was treated with TfOH, 
which underwent the cyclisation cascade to give the hydroxy 
3-spiropiperidine, which was oxidised with IBX to 3-
spiropiperidine 74 (Scheme 21). The substituent on the alkyne 
was varied to different substituted aromatics, although the 
resultant spirocycle formed remained unchanged throughout 
the study. The ketone of the spirocycle provides a handle for 
further elaboration. 
 
Reddy and co-workers presented one example of the 
synthesis of 3-spiropiperidines with a Prins/ene cascade 
process.
30
 The reaction proceeded under mild conditions 
between diene 75 and an aromatic aldehyde 76 to give 3-
spiropiperidine 77 in good yield (Scheme 22).  
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Scheme 21 Tandem semi-pinacol rearrangement/alkyne-aldehyde metathesis to 
furnish 3-spiropiperidines. 
 
 
Scheme 22 Tandem Prins cyclisation strategy for the synthesis of 3-
spiropiperidines 
A catalytic asymmetric conjugate addition of α-
cyanoketones to vinyl ketones to generate new quaternary 
stereogenic centres was reported by Shibasaki in 2010.31 The 
conjugate addition between ketone 78 and Michael acceptor 
79, using Y(OiPr)3 with an amide ligand 80, proceeded in high 
yield and excellent enantioselectivity (Scheme 23). Nitrile 81 
was reduced with Raney Ni in AcOH under a H2 atmosphere, 
which induced an intramolecular condensation to form a cyclic 
imine, which was then further reduced to give 3-
spiropiperidine 82 in good yield.  
Described by Shibuya in 2017, a Brønsted acid-catalysed 
intramolecular hydroalkylation/reduction of unactivated 
alkynes gave rise to one example of a 3-spiropiperidine 
synthesis.32 Treatment of alkyne 83 with catalytic Tf2NH 
followed by reduction of the enamine with Et3SiH gave 3-
spiropiperidine 84 in good yield (Scheme 24). 
 
Scheme 23 Conjugate addition of an α-cyanoketone to a vinyl ketone to give a 3-
spiropiperidine precursor.  
 
Scheme 24 Sequential hydroalkylation and silane reduction of unactivated 
alkynes to give a 3-spiropiperidine.  
Wang demonstrated the use of substituted fulvenes 85 as 
6π dipolarophiles in a [6+3] cycloaddition with azomethine 
ylides generated from precursor 86 (Scheme 25).
30
 Catalysed 
by Cu(I) with chiral ligand 87, the enantioselective reaction 
allowed the synthesis of 3-spiropiperidines 88 in good to high 
yields with high enantioselectivity. The reaction was reported 
with a range of fulvene derivatives which consequently 
accessed different sized carbocyclic spirocycles. 
 
 
Scheme 25 Enantioselective [6+3] cycloaddition of substituted fulvenes with 
azomethine ylides. 
Harrity and co-workers introduced in 2016, a new 
palladium-catalysed method for the synthesis of functionalised 
piperidines.
34
 Upon treatment with palladium, cyclic 
carbamate 90 underwent loss of CO2 and a formal [4+2] 
cycloaddition comprising of an allylation-condensation 
sequence. Use of a 1,3-dicarbonyl with a cyclic lactone 89, 
where the ketone substituent can be either aliphatic or 
aromatic, gave spirocyclic imine 91 in high yield and excellent 
%ee (Scheme 26). The imine was then reduced to give 3-
spiropiperidine 92.  
 
 
Scheme 26 Sequential allylation-condensation between a cyclic carbamate and a 
1,3-dicarbonyl for 3-spiropiperidine synthesis.  
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The SpiroChem library
35
 was utilised by Carreira for the 
synthesis of 3-spiropiperidines, starting with spiro building 
block 93.
36
 Ring opening of one oxetane ring of 93 with a 
lithium-enolate furnished 94, which after reduction, gave a 
diol which underwent double mesylation to give 95 (Scheme 
27). Heating 95 in the presence of piperonylamine induced 
double displacement to give 3- spiropiperidine 96 in good yield 
over 3 steps.  
 
 
Scheme 27 Double displacement of a diol generated from ring opening of 2,6-
dioxaspiro[3.3]heptane.  
Diastereoselective ring-rearrangement metathesis was 
reported by Lee in 2012.
37
 Alcohol 97 was oxidised to the 
aldehyde, and subsequent amine deprotection with TFA gave 
the aminal, which eliminated to give imine 98. Reduction of 
the imine with NaBH4 gave the 3-spiropiperidine, which was 
deprotected with ammonium fluoride to give 99 (Scheme 28). 
  
 
Scheme 28 Aminal formation and elimination followed by reduction to give the 
3-spiropiperidine core of nitramine.  
4. 4-Spiropiperidines 
4.1 4-Spiropiperidine formation on a preformed piperidine ring 
All the reported syntheses of 4-spiropiperidines arise from the 
formation of a carbocyclic or heterocyclic ring on a preformed 
piperidine ring. Where the methods involve intramolecular 
cyclisations via displacement, lactamisation, or ring closing 
metathesis, the key bond forming step is the construction of 
the fully substituted spiro-centre. Other methods for the 
formation of the 4-spiropiperidine include Rh(III) catalysed C-H 
activation, Fischer-indole syntheses, and acid-mediated 
cyclisations.  
Lee and co-workers developed a stereoselective synthesis 
of 4-spiropiperidines for use in studies as BACE-1 aspartyl 
protease inhibitors in 2013.38 Base-mediated addition of 
chloroform to optically active 100 followed by a modified 
Corey-Link reaction
39
 furnished azide 101 with the correct 
stereochemistry, which was then reduced with Zn/AcOH to 
amine 102 (Scheme 29). Acylation of amine 102 with mono-
ethyl malonate gave malonamide 103 and intramolecular 
Dieckmann cyclisation gave 4-spiropiperidine 104 in excellent 
yield. The target 4-spiropiperidine 105 was reached in 3 
further steps – decarboxylation, reduction and elimination. An 
alternative approach to a similar compound was reported by 
Henegar in 2013
40
 via a stereospecific Jocic reaction,
41
 
whereby trichloromethylcarbinol 107 was converted to the α-
amino ester 108, followed by amidation with ethyl malonyl 
chloride (Scheme 30). Subsequent Dieckmann cyclisation and 
decarboxylation gave the 3-spiropiperidine 110 in good yield 
over 3 steps. 
 
SnAP reagents were also used for the synthesis of a 4-
spiropiperidine.
42
 Under the same conditions as presented in 
Scheme 6,
13
 use of piperidin-4-one 112 enabled the synthesis 
of 4-spiropiperidine 114 with a heterocyclic spirocycle (Scheme 
31). The protocol yields spirocyclic morpholines and 
piperazines bearing different nitrogen containing heterocycles 
at the spiro-centre. 
 
 
Scheme 29 Corey-Link reaction followed by intramolecular Dieckmann 
cyclisation. 
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Scheme 30 Stereospecific Jocic reaction for the conversion of a 
trichloromethylcarbinol to an α-amino ester. 
 
Scheme 31 SnAP reagents for the synthesis of spirocyclic morpholines and 
piperazines. 
An alternative approach to the 4-spiropiperidine BACE-1 
aspartyl protease target 118 was reported by Martinez-Alsina 
in 2017.43 Amine 116 was accessed through a 
diastereoselective Overman rearrangement of 
trichloroacetimidate 115 followed by DIBAL-H reduction of the 
resultant trichloroacetamide (Scheme 32). Acylation of amine 
116 with acroloyl chloride gave diene 117 which underwent 
ring closing metathesis to give 4-spiropiperidine 118 in high 
yield. The synthesis was employed to generate novel 
spirocyclic sultams and lactams for SAR studies.  
 
 
Scheme 32 Ring closing metathesis on a precursor generated from an Overman 
rearrangement. 
Miel presented the synthesis of a spiropiperidine analogue 
of the eastern part of the anti-HIV drug maraviroc, utilising the 
first reported synthesis of nitro piperidine 119.
44
 Michael 
addition of nitro piperidine 119 to methyl acrylate gave nitro 
ester 120, which was reduced by catalytic hydrogenation 
(Scheme 33). The reduced amino intermediate underwent 
spontaneous lactamisation to give 4-spiropiperidine 121 in 
high yield over two steps. Smith and co-workers employed a 
similar strategy of obtaining the spirocycle as Miel by 
reduction and spontaneous cyclisation in 2016.
45
 The anion of 
cyano-piperidine 122 formed with LDA was quenched with 
ClCH2I to give alkylated piperidine 123 (Scheme 34).
 
Reduction 
of the nitrile gave the amine, which cyclised to form the 
azetidine. Subsequent protection gave 4-spiropiperidine 124 in 
moderate yield. The same strategy was employed to form the 
pyrrolidine of 127 from cyano-piperidine 125.  
 
 
Scheme 33 Nitro group reduction and lactamisation to form the spiro-γ-lactam. 
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Scheme 34 Spriocycle formation by nitrile reduction and subsequent cyclisation 
by displacement. 
Potent, selective CNS-targeted inverse agonists of the 
ghrelin receptor, each bearing a 4-spiropiperidine core were 
reported by McClure and coworkers.46 The general synthesis of 
the analogues began with addition of ester 128 into ClCH2I to 
give chloride 129, and reduction of the ester and subsequent 
oxidation gave aldehyde 130 (Scheme 35). Reductive 
amination with aminoindane 131 followed by intramolecular 
cyclisation to displace the chloride formed oxetane 132 in 
excellent yield.  
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Scheme 35 Reductive amination and chlorine displacement to form the azetidine 
of the 4-spiropiperidine.  
The synthesis of spirocyclic benzofurans bearing a 4-
spiropiperidine through an intramolecular Heck cyclisation was 
developed by Leflemme.47 Bromide 133 was treated with 
Herrmann-Beller catalyst 134 which underwent intramolecular 
cyclisation to give benzofuran 135 in high yield (Scheme 36). 
The cyclisation was demonstrated with different benzyl alcohol 
substitution around the phenyl ring. Enamine 135 then 
underwent reduction and global deprotection to give 4-
spiropiperidinyl benzofuran 136 in excellent yield. Chabaud 
and co-workers reported the synthesis of similar spirocyclic 
substituted benzofurans, as well as indanes and benzopyrans 
through rhodium(III)-catalysed C-H activation (Scheme 37).48 
Direction from the methoxy-amide 137 formed the indane ring 
and enamine 138 in good yield. The enamine 138 was treated 
with catalytic TFA to induce cyclisation to form the tetracyclic 
piperidine 139. The same method has also been utilised for the 
synthesis of 3-spiropiperidines.48  
Clayden described an electrophile-induced dearomatizing 
spirocyclisation of N-arylisonicotinamides in 2008.49 Treatment 
of pyridine 140 with Tf2O induced an intramolecular 
spirocyclisation to give dihydropyridine 141 in excellent yield 
(Scheme 38). High pressure hydrogenation of 141 gave 4-
spiropiperidine 142. The procedure presented generates 4-
spiropiperidines bearing a substituted oxindole as the 
spirocycle. This work was developed further in 2013 
demonstrate the robustness with the use of substituted N-
alkenyl pyrdinecarboxamides.50 
 
 
 
Scheme 36 Intramolecular Heck cyclisation for synthesis of spirocyclic 
benzofurans. 
Yang and co-workers reported the discovery of P2Y1 
antagonists as novel antiplatelet agents, with analogues 
bearing a 4-spiropiperidine unit in 2014.
51
 Spiroindole 145 was 
synthesised via a Fischer indole synthesis between hydrazine 
143 and aldehyde 144 under acidic conditions (Scheme 39). 
The resultant indolenine was reduced with NaBH4 to give 4-
spiropiperidine 145. The bromide was then used as a handle 
for Suzuki couplings to generate aromatic analogues.  
 
 
Scheme 37 Rhodium catalysed C-H activation for the synthesis of spiropiperidine 
derivatives. 
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Scheme 38 Intramolecular dearomatizing spirocyclisation for synthesis of 
dihydropyridines.  
 
Scheme 39 Fischer indole to introduce the spiroindolenine. 
A Fischer indole approach was also reported by Ruijter in 
2016 for use in Ugi-type reactions to generate spirocyclic 
indolenines (Scheme 40).52 The indolenine 148 was not 
reduced, instead, addition of an isocyanide and trapping with a 
carboxylic acid generated the 4-spiropiperidine Ugi product 
149 in good to excellent yields. Substituents on the aromatic 
ring of the resultant indole have been varied, along with 
different isocyanides and carboxylic acids, however, 
substitution on the piperidine ring has not been reported.  
 
 
 
Scheme 40 Fischer indole synthesis followed by Ugi reaction. 
A novel rhodium-catalysed asymmetric hydrogenation of a 
spirocyclic indone was reported by Limanto for the synthesis of 
a tertiary carbinamide.53 Addition of Grignard 151 into Michael 
acceptor 150, formed from the condensation of N-Boc 
piperidone with Meldrum’s acid, followed by hydrolysis gave 
carboxylic acid 152 in high yield (Scheme 41). Formation of the 
acid chloride 153 with oxalyl chloride allowed for AlCl3-
mediated intramolecular Friedel-Crafts cyclisation to occur. 
The acidic conditions deprotected the amine, which was re-
protected to give indone 154 bearing a non-substituted 4-
spiropiperidine in good yield. Bandarage demonstrated a 
similar strategy, using Eaton’s reagent
54
 to perform the 
cyclisation directly onto the acid 155 to form the indane ring of 
156 (Scheme 42).
55
 
 
 
 
Scheme 41 Ring closing Friedel-Crafts acylation for 4-spiropiperidine synthesis.   
Stanetty reported the synthesis of benzo- and thieno-fused 
spirolactams in 2009. Lithiation of thiophene 158 and addition 
to N-methyl piperidone 157 followed by acid mediated 
cyclisation gave 4-spiropiperidine 159 in high yield (Scheme 
43).
56 
 
 
 
Scheme 42 Intramolecular cyclization utilizing Eaton’s reagent 
 
 
Scheme 43 Acid mediated cyclisation for thiophene-fused spirocycles. 
 
 A synthesis of substituted spiro-chromanones as histone 
deacetylase inhibitors was presented by Thaler.
57,58
 N-Phenyl 
piperidone 160 was treated with hydroxy ketone 161 in the 
presence of pyrrolidine to give 4-spiropiperidine 162 in 
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moderate yield (Scheme 44). The aromatic bromide was then 
used as a handle for elaboration through cross couplings. 
Brown reported the discovery of spirofused piperazine and 
diazepine amides as selective histamine-3 antagonists bearing 
4-spiropiperidines.
59
 Wittig methylenation of N-Cbz piperidone 
163 furnished exocyclic methylene 164 and cyclopropanation 
was achieved with CuCN and ethyldiazoacetate to give 4-
spiropiperidine 165 in moderate yield (Scheme 45).
 
The ester 
was then hydrolysed to the carboxylic acid for a series of 
amide couplings. The synthesis of 4-spiropiperidines bearing 
cyclobutane, azetidine and pyrrolidine and piperidine rings are 
also presented for assay screening.  
 
 
 
Scheme 44 Spirocyclic chromanone synthesis from N-phenyl piperidone. 
 
 
Scheme 45 Cyclopropanation of an exocyclic double for spirocycle synthesis. 
The use of spiropiperidine hydantoins as a novel class of 
antimalarial agents was evaluated by Meyers in 2015.60 The 
hydantoin was installed on N-Boc piperidone 166 with KCN and 
(NH4)2CO3 to give spirocyclic hydantoin 167 in good yield 
(Scheme 46). The hydantoin was further substituted and the 
piperidine nitrogen was elaborated with different aromatic 
systems. 
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Scheme 46 Spiropiperidine hydantoin synthesis. 
The synthesis of spiropiperidine lactam acetyl-CoA 
carboxylase inhibitors was developed by Menhaji-Klotz and 
coworkers.
61
 For analogue synthesis, N-Boc piperidone 168 
was synthesised via enolate chemistry into the respective halo-
pyrazole (Scheme 47).
 
Treatment of 168 with DPPA induced a 
Curtius rearrangement to isocyanate 169, which was quenched 
through addition of the lithiated pyrazole to give spirolactam 
170 in excellent yield. A similar strategy was employed by 
Rotstein and co-workers for their synthesis of CCR5 
antagonists.
62
 N-Cbz piperidone 172 underwent a Curtius 
rearrangement, and the subsequent isocyanate was trapped 
intramolecularly by the alcohol, furnishing the spirocyclic 
carbonate 173 in high yield (Scheme 48). The synthesis of both 
five and six membered cyclic carbonates are presented. 
 
 
 
Scheme 47 Lithiated pyrazole addition into an isocyanate to form a spirocyclic 
lactam.  
 
 
 
Scheme 48 Alcohol-mediated attack into an isocyanate for spirocyclic carbamate 
synthesis.  
 
4.2 4-Spiropiperidine formation on a preformed 
carbocyclic/heterocyclic ring. 
 
Interestingly, at the time of writing we were unable to find a 
literature example where the 4-spiropiperidine was formed as 
a result of the synthesis of the piperidine ring. Few examples 
of the preformed carbocyclic ring are described in Troin’s 
review in 2009.
3
  
Conclusions 
We have presented an overview of the past 10 years of the 
synthesis of 2-, 3- and 4-spiropiperidines. Whilst the syntheses 
of 2-spiropiperidines are mainly for methodology purposes 
and natural product synthesis, 3- and 4-spiropiperidines have 
held their place as useful scaffolds in drug discovery. It is 
interesting to note the trend in how the spirocycles are 
formed; 2-spiropiperidines tend to arise from annulation of a 
preformed carbocyclic ring, 4-spiropiperidines arise exclusively 
from annulation of a preformed piperidine ring, and 3-
spiropiperidines are represented by an approximate 1:1 ratio 
of the two approaches. The majority of 2-spiropiperidine 
syntheses arise from piperidine formation, presumably a 
consequence of the difficulty of achieving double substitution 
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directly on the carbon alpha to the nitrogen. New methods for 
achieving double substitution of this carbon atom to install 
spirocycles would be a novel approach. The presented 
examples of 4-spiropiperidine syntheses all require a 
preformed piperidine ring. Often, the key challenge for these 
syntheses lie in the formation of the spiro-centre, not the 
subsequent ring forming reaction. Methods for the 
enantioselective synthesis of 4-spiropiperidines are required. 
Additionally, nearly all the examples of 4-spiropiperidine 
syntheses show unsubstituted piperidines, highlighting the 
opportunity for the development of methods to access 4-
spiropiperidines which are substituted on the piperidine ring. 
3-Spiropiperidines are represented by a very diverse range of 
chemistry, including enantioselective syntheses, furnishing 
substituted piperidines and spirocycles which have been well 
explored. 
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